BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38571471)

  • 21. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve.
    Oriol B; Barrio A; Pacheco A; Serna J; Zuzuarregui JL; Garcia-Velasco JA
    Fertil Steril; 2008 Nov; 90(5):1579-82. PubMed ID: 18054933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study.
    Tzeng CR; Huang Z; Asada Y; Zhang C; Ho MT; Li RHW; Kim JH; Govindarajan M; Vuyavanich T; Sini I; Wong PS; Singh S; Lin WY; Ho NT
    Hum Reprod; 2023 Jul; 38(7):1368-1378. PubMed ID: 37105234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy.
    Gadducci A; Cosio S; Fanucchi A; Tana R; Manacorda S; Pistolesi S; Strigini FL
    Anticancer Res; 2016 Jul; 36(7):3477-82. PubMed ID: 27354611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Mangili G; Cioffi R; Danese S; Frigerio L; Ferrandina G; Cormio G; Rabaiotti E; Scarfone G; Gadducci A; Bergamini A; Pisano C; Candiani M
    Gynecol Oncol; 2018 Dec; 151(3):449-452. PubMed ID: 30266260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
    Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
    Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
    Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
    Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis.
    Brouwer J; Laven JS; Hazes JM; Schipper I; Dolhain RJ
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1534-8. PubMed ID: 23554429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
    Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
    Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels.
    Benian A; Guralp O; Uzun DD; Okyar A; Sahmay S
    Gynecol Endocrinol; 2013 Mar; 29(3):226-9. PubMed ID: 23428228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.